Back to results
US 6,552,077 B2Granted
Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
AssigneeExocell, Inc.
InventorMargo P. Cohen
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.
Claims9
A therapeutic composition comprising a pharmaceutically acceptable carrier and a compound selected from those having the following structure:
- wherein:
- R′3, R′4, R′5, R′6, R2, R3, R4, R5, and R6 are the same or different and are hydrogen, chlorine, bromine, fluorine, iodine, ethyl, ethoxy, methoxy, hydroxy, phosphate, sulfate, nitrate, amino or ethyl, and R2 and R6 are both not chlorine when R′3, R′4, R′5, R′6, R3, R4 and R5 are hydrogen;
- X is hydrogen, sodium, potassium or lithium.
A therapeutic composition comprising a pharmaceutically acceptable carrier and 2-[(3-chlorophenyl) amino] phenylacetic acid.
A therapeutic composition comprising a pharmaceutically acceptable carrier and 2-[(2-chlorophenyl) amino] phenyl acetic acid.
Dependencies are inferred from the claim text.